UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2059-13
Program Prior Authorization/Medical Necessity Buprenorphine/Naloxone Products
Medication Suboxone® * (Brand Only)
P&T Approval Date 7/2015, 10/2016, 3/2017, 9/2017, 9/2018, 7/2019, 7/2020, 11/2020,
11/2021, 1/2023, 2/2024, 4/2025
Effective Date 7/1/2025
1. Background
Suboxone* contains buprenorphine, a narcotic and naloxone, an opiate antagonist.
Buprenorphine, like other opioids, has the potential for being abused. Naloxone is used to guard
against misuse by blocking the effects of opiates if the drug is manipulated for injection.
This program requires a member to meet treatment criteria prior to the coverage of
buprenorphine/naloxone combination products. It also requires the member to try the preferred
combination product buprenorphine/naloxone (generic Suboxone) or Zubsolv prior to receiving
coverage for Suboxone *.
2. Coverage Criteriaa, b:
A. Initial Authorization
1. Suboxone* (Brand Only) will be approved based on both of the following criteria:
a. The patient is being treated for opioid dependencec
-AND-
b. Both of the following:
i. One of the following:
(a) Submission of medical records (e.g., chart notes) documenting an inadequate
response to a minimum 30-day trial of Zubsolv. (30-day trial must be completed
prior to Prior Authorization/Medical Necessity request.)
(b) Submission of medical records (e.g., chart notes) documenting the member has
experienced adverse effects or has a contraindication to Zubsolv, including the
manifestation of the adverse reaction or reason for contraindication
-AND-
ii. One of the following:
(a) Submission of medical records (e.g., chart notes) documenting an inadequate
response to a minimum 30-day trial of buprenorphine/naloxone (generic
Suboxone). (30-day trial must be completed prior to Prior Authorization/Medical
© 2025 UnitedHealthcare Services, Inc.
1
Necessity request.)
(b) Submission of medical records (e.g., chart notes) documenting the member has
experienced adverse effects or has a contraindication to generic
buprenorphine/naloxone (generic Suboxone) including the manifestation of the
adverse reaction or reason for contraindication
Authorization will be issued for 12 months.
B. Reauthorization:
1. Suboxone* (Brand Only) will be approved based on the following criterion:
a. Documentation of positive clinical responsec
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
b Review not required for plans sitused in the state of Illinois.
c Plans sitused in Nevada are not subject to clinical criteria. Only step therapy may be required.
3. Additional Clinical Rules:
• Supply limits may be in place.
• Suboxone (Brand Only) is typically excluded from coverage. Tried/Failed criteria may be in
place. Please refer to plan specifics to determine exclusion status.
Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Suboxone [package insert]. Richmond, VA: Indivior Inc.; December 2023.
2. Zubsolv [package insert]. Morristown, NJ: Orexo US, Inc.; December 2023.
3. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused
Update [published correction appears in J Addict Med. 2020 May/Jun;14(3):267]. J Addict Med.
2020;14(2S Suppl 1):1-91. doi:10.1097/ADM.0000000000000633
Program Prior Authorization/Medical Necessity – Buprenorphine/Naloxone
Products
Change Control
Date Change
7/2015 New Program
10/2016 Annual update. Decreased reauthorization period from 24 months to 12
months. Updated references.
3/2017 Administrative update. Removed requirement for medical record
submission to verify opioid dependence diagnosis. Updated references.
9/2017 Changed reference from intolerance to adverse reaction to Zubsolv.
© 2025 UnitedHealthcare Services, Inc.
2
Removed DEA waiver requirement.
9/2018 Annual review. Removed reference to brand Suboxone tablets (brand
no longer available). Updated references.
7/2019 Removed generic Suboxone and buprenorphine/naloxone tablets from
medications covered by criteria. Added criteria for DATA2000
prescriber.
7/2020 Annual review. Updated references. Clarified timing of 30 day trial.
11/2020 Removed criteria for DATA2000 prescriber. Removed pain
management confirmation. Updated medical records requirement.
11/2021 Annual review. Updated references.
1/2022 Administrative change. Illinois footnote added. Criteria retired 1/2019
for Illinois.
1/2023 Updated background to include additional qualified practitioners that
may prescribe buprenorphine for the treatment of opioid use disorder.
Updated references.
2/2024 Removed Bunavail from program, it is off the market. Added Nevada
mandate. Updated references.
4/2025 Annual review. Updated background and references.
© 2025 UnitedHealthcare Services, Inc.
3